Serum MMP3 and IL1-RA levels may be useful biomarkers for detecting asthma and chronic obstructive pulmonary disease overlap in patients with asthma.
Asthma-chronic obstructive pulmonary disease overlap
Interleukin 1 receptor antagonist
Matrix metalloproteinase 3
Serum marker
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
21
02
2023
revised:
16
08
2023
accepted:
17
10
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Asthma and chronic obstructive pulmonary disease (COPD) overlap (ACO) is characterized by concurrent features of asthma and COPD. Since disease pathogenesis, severities, and treatments differ between asthma and ACO, it is important to differentiate them. To clarify and compare the characteristics of ACO and asthma and identify the serum biomarkers for differentiating them, especially in older patients. This study used the data of 639 participants from the nationwide cohort study, the NHOM-Asthma study, an asthma registry in Japan, with complete information on smoking history, respiratory function, and serum biomarkers. ACO was defined as the self-reported comorbidity of COPD or emphysema, or with obstructive pulmonary function and smoking history (pack-years≥10). The clinical characteristics of patients with ACO and asthma without COPD were compared. The serum biomarkers for differentiation were examined using receiver operating characteristic curves and multivariable analysis. The associations between the biomarkers and age were also analyzed. Of the 639 asthma patients, 125 (19.6%) were diagnosed with ACO; these patients were older and male-dominant and had a higher prevalence of comorbidities such as hypertension, diabetes, and stroke. Among the serum biomarkers that were significantly different between ACO and asthma without COPD, the YKL-40/CHI3L1, MMP3, and IL-1RA levels showed a high area under the curve for discriminating ACO. Only the MMP3 and IL-1RA levels were significantly higher among ACO patients, regardless of age and sex; the YKL-40/CHI3L1 levels were not different due to the effect of age. MMP3 and IL-1RA may be useful serum biomarkers for distinguishing ACO from asthma.
Sections du résumé
Background
UNASSIGNED
Asthma and chronic obstructive pulmonary disease (COPD) overlap (ACO) is characterized by concurrent features of asthma and COPD. Since disease pathogenesis, severities, and treatments differ between asthma and ACO, it is important to differentiate them.
Objective
UNASSIGNED
To clarify and compare the characteristics of ACO and asthma and identify the serum biomarkers for differentiating them, especially in older patients.
Methods
UNASSIGNED
This study used the data of 639 participants from the nationwide cohort study, the NHOM-Asthma study, an asthma registry in Japan, with complete information on smoking history, respiratory function, and serum biomarkers. ACO was defined as the self-reported comorbidity of COPD or emphysema, or with obstructive pulmonary function and smoking history (pack-years≥10). The clinical characteristics of patients with ACO and asthma without COPD were compared. The serum biomarkers for differentiation were examined using receiver operating characteristic curves and multivariable analysis. The associations between the biomarkers and age were also analyzed.
Results
UNASSIGNED
Of the 639 asthma patients, 125 (19.6%) were diagnosed with ACO; these patients were older and male-dominant and had a higher prevalence of comorbidities such as hypertension, diabetes, and stroke. Among the serum biomarkers that were significantly different between ACO and asthma without COPD, the YKL-40/CHI3L1, MMP3, and IL-1RA levels showed a high area under the curve for discriminating ACO. Only the MMP3 and IL-1RA levels were significantly higher among ACO patients, regardless of age and sex; the YKL-40/CHI3L1 levels were not different due to the effect of age.
Conclusion
UNASSIGNED
MMP3 and IL-1RA may be useful serum biomarkers for distinguishing ACO from asthma.
Identifiants
pubmed: 38020287
doi: 10.1016/j.waojou.2023.100840
pii: S1939-4551(23)00100-X
pmc: PMC10663683
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100840Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
Maho Suzukawa received Grants from AstraZeneca, GlaxoSmithKline, Kyorin, Kyowa Kirin, Daiichi Sankyo, Sanofi, and Shionogi and honoraria for lectures from AstraZeneca, Novartis Pharma, GlaxoSmithKline, and Sanofi. Nobuharu Ohshima received honoraria for lectures from AstraZeneca, Novartis Pharma, GlaxoSmithKline, and Sanofi. Yuma Fukutomi received honoraria for lectures from Thermo Fisher Diagnostics, Torii Pharmaceutical, Novartis Pharma, Kyorin, Sanofi, and Taiho Pharmaceutical. Masami Taniguchi received Grants from GlaxoSmithKline and honoraria for lectures from Novartis Pharma, GlaxoSmithKline, and Sanofi. Masahiro Akishita received Grants from Astellas Pharma, Bayer HealthCare, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Kracie Pharma, Mitsubishi-Tanabe Pharma, MSD, and Ono Pharmaceutical and honoraria for lectures from Daiichi Sankyo, MSD, Toa Eiyo, and Towa Pharmaceutical.
Références
Respirology. 2015 Aug;20(6):940-6
pubmed: 25998444
Respirology. 2015 Apr;20(3):413-8
pubmed: 25565363
Am J Respir Crit Care Med. 2010 Feb 15;181(4):315-23
pubmed: 19892860
Eur Respir J. 2018 Apr 19;51(4):
pubmed: 29563173
J Epidemiol. 2007 Mar;17(2):54-60
pubmed: 17420613
Eur Respir J. 2015 Mar;45(3):635-43
pubmed: 25431272
Am J Respir Crit Care Med. 1999 Jun;159(6):1985-91
pubmed: 10351949
Int J Chron Obstruct Pulmon Dis. 2016 Sep 07;11:2117-2123
pubmed: 27660429
Clin Chim Acta. 2011 Apr 11;412(9-10):709-12
pubmed: 21272568
Respir Res. 2018 Mar 27;19(1):47
pubmed: 29580282
N Engl J Med. 2000 Sep 7;343(10):732-4
pubmed: 10974140
Allergol Int. 2017 Oct;66(4):624-626
pubmed: 28285848
Am J Respir Crit Care Med. 2012 Jul 15;186(2):155-61
pubmed: 22561964
Acta Biomater. 2019 Jul 15;93:123-134
pubmed: 31029831
Allergy. 2018 Feb;73(2):284-294
pubmed: 28722758
Clin Exp Allergy. 1994 Jun;24(6):530-9
pubmed: 7922774
BMC Pulm Med. 2020 Nov 16;20(1):302
pubmed: 33198714
N Engl J Med. 2015 Sep 24;373(13):1241-9
pubmed: 26398072
BMC Immunol. 2020 Oct 1;21(1):52
pubmed: 32998687
Am J Respir Crit Care Med. 2008 Aug 1;178(3):218-224
pubmed: 18480428
Mediators Inflamm. 2002 Oct;11(5):307-12
pubmed: 12467523
Allergol Int. 2023 Jan;72(1):63-74
pubmed: 35791991
N Engl J Med. 2007 Nov 15;357(20):2016-27
pubmed: 18003958
Am J Respir Crit Care Med. 2016 Feb 1;193(3):251-8
pubmed: 26414484
Int Arch Allergy Immunol. 2010;153(3):280-7
pubmed: 20484927
J Allergy Clin Immunol Pract. 2019 Jan;7(1):134-145.e1
pubmed: 29981861
Clin Exp Allergy. 2013 Jun;43(6):608-15
pubmed: 23711122
Allergol Int. 2023 Apr;72(2):252-261
pubmed: 36371246
Eur J Immunol. 2016 Dec;46(12):2761-2766
pubmed: 27682622
Eur Respir J. 2021 Dec 31;59(1):
pubmed: 34667060
J Allergy Clin Immunol. 2014 Mar;133(3):632-9.e5
pubmed: 24361081
J Exp Med. 1989 Apr 1;169(4):1449-59
pubmed: 2926329
Circ Res. 2003 Jun 13;92(11):1254-61
pubmed: 12750310
J Exp Med. 1987 Oct 1;166(4):1084-97
pubmed: 2443596
Respirology. 2016 Apr;21(3):410-8
pubmed: 26450153
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1495-1510
pubmed: 33629319
Lancet. 2018 Feb 24;391(10122):783-800
pubmed: 29273246
J Allergy (Cairo). 2011;2011:861926
pubmed: 22121384
Int J Chron Obstruct Pulmon Dis. 2018 Jan 30;13:409-418
pubmed: 29430175
Ann Am Thorac Soc. 2018 Jan;15(1):33-41
pubmed: 28910142
Am J Respir Crit Care Med. 2016 May 1;193(9):949-56
pubmed: 26756066
Biochem J. 2002 Jul 1;365(Pt 1):119-26
pubmed: 12071845
Matrix Biol. 2015 May-Jul;44-46:167-74
pubmed: 25686691
Respir Res. 2011 Nov 04;12:146
pubmed: 22054035
Allergol Int. 2021 Jul;70(3):281-290
pubmed: 33962864
Ann Am Thorac Soc. 2016 Nov;13(11):2064-2077
pubmed: 27831798
Int J Chron Obstruct Pulmon Dis. 2015 Oct 09;10:2169-76
pubmed: 26491283
Int J Chron Obstruct Pulmon Dis. 2015 Mar 18;10:595-602
pubmed: 25834418
Am J Respir Crit Care Med. 2006 Jul 1;174(1):6-14
pubmed: 16556692
Respirology. 2012 Aug;17(6):1006-12
pubmed: 22591289
Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582
pubmed: 28128970
Respir Med. 2016 Jan;110:1-11
pubmed: 26525374
Nat Rev Immunol. 2008 Mar;8(3):183-92
pubmed: 18274560
Physiol Rev. 2007 Jul;87(3):1047-82
pubmed: 17615396
Am J Respir Crit Care Med. 2019 Jun 15;199(12):1575-1577
pubmed: 30917289